Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Ascletis to Start Zhejiang Province Trial of Generic HIV/AIDS Drug for COVID-19

publication date: Feb 17, 2020

Ascletis Pharma of Hangzhou reported that Zhejiang Province authorities approved a trial of ritonavir in patients with COVID-19. Ritonavir is a generic version of AbbVie’s Norvir, an oral antiretroviral that has been in use for over 20 years to treat HIV/AIDS. The study is being run jointly by Ascletis and the First Affiliated Hospital of Zhejiang University School of Medicine. According to Ascletis, it is currently conducting four clinical trials that combine ritonavir and ASC09, a protease inhibitor that is also being tested as an HIV treatment. More details....

Stock Symbol: (HK:1672)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.